Why the study?
What are the clinically significant drug interactions associated with propafenone in patients with cardiac arrhythmias?
What are the clinically significant drug interactions associated with propafenone in patients with cardiac arrhythmias?
Detailed knowledge of propafenone's drug interactions is essential for its safe administration in patients with cardiac arrhythmias.
Requires pre-prescription interaction screening for propafenone in arrhythmias; leaves open prospective assessment of clinical impact.
Propafenone is a Class IC antiarrhythmic drug that has been under investigation for over 10 years and is on the threshold of release for general use. Clinical trials have been completed that present compelling evidence of the safety and efficacy of the drug for the treatment of malignant ventricular arrhythmias. As with other potent antiarrhythmic agents, propafenone has the propensity to interact with a variety of other drugs, and these interactions are of critical importance to physicians who will prescribe the drug to patients with cardiac arrhythmias. A particularly detailed knowledge of the interactions between propafenone and such commonly used drugs as anticoagulants, digoxin, cimetidine, other antiarrhythmics, and even food is essential to its safe administration. This paper reviews current information regarding the drug interactions of propafenone so that, once released and available, it will be used appropriately and safely.
No takes yet. Share an insight, caveat, or question.
Stohler et al. (1987) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: